Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines

Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

(2010) Andrew Y. Choo et al.   CELL CYCLE

mTOR inhibitors for hepatocellular cancer: a forward-moving target

(2009) Gerhard Treiber   Expert Review of Anticancer Therapy

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma

(2009) Hideo A. Baba et al.   LIVER INTERNATIONAL

Effect of Low-Dose Rapamycin on Tumor Growth in Two Human Hepatocellular Cancer Cell Lines

(2009) M. Heuer et al.   TRANSPLANTATION PROCEEDINGS

Reconstructing networks of pathways via significance analysis of their intersections

(2008) Mirko Francesconi et al.   BMC BIOINFORMATICS

Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1alpha and VEGF in Hepatocellular Carcinoma

(2008) Wei Wang et al.   DIGESTIVE DISEASES AND SCIENCES

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

(2008) Zheng Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY